Blood Cancer United, a nonprofit focused on blood cancer research, advocacy and patient support, has acquired the remaining supply of investigational therapy luveltamab tazevibulin to preserve access for children with CBFA2T3-GLIS2-rearranged acute myeloid leukemia through the FDA’s compassionate use pathway.
The therapy, an antibody-drug conjugate targeting folate receptor 1, no longer had a development path for its primary indication in adult cancer. As a result, a compassionate use program for pediatric patients was discontinued, according to a June 11 news release.
CBFA2T3-GLIS2-rearranged acute myeloid leukemia is diagnosed in an estimated 17 children in the U.S. each year and has a survival rate of 15% to 30%. Blood Cancer United said it acquired the existing drug supply and rights needed to make the therapy available at no cost to patients for this specific pediatric use.
The organization said its role is limited to preserving access to the existing supply and that it will not commercialize the drug. The effort is funded through Dare to Dream, a Blood Cancer United project focused on pediatric cancer treatment and care.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
